NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NewAmsterdam Pharma Co N.V. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $226.5K in total
- Open-market sells
- 3 filings
- 3 insiders, $6.59M in total
- Insiders trading
- 4
- Net value
- −$6.36M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NewAmsterdam Pharma Co N.V., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer | 792,923 | Sep 15, 2026 | 4 |
| Smither John W | Director | 8,760 | Sep 9, 2026 | 2 |
| Gunning Robert William | Vice President, Controller | 3,200 | Sep 3, 2026 | 1 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 69,302Indirect | Aug 25, 2026 | 4 |
| Kooij Louise Frederika | Chief Accounting Officer | 24,353 | Jul 22, 2026 | 7 |
| Lange Louis G | Director | 10,360 | Mar 12, 2026 | 3 |
| Somaiya Mayur Ian | Chief Financial Officer | 58,382 | Jan 22, 2026 | 2 |
| Lewis William | Director | 10,360 | Jan 9, 2026 | 1 |
| Gulfo Adele M. | Director | 14,260 | Jan 9, 2026 | 1 |
| McKenna Mark C. | Director | 10,360 | Jan 9, 2026 | 1 |
| van der Kamp Hilde Johanna | Director | 10,360 | Jan 9, 2026 | 1 |
| Topper James N | Director | 3,028,524Indirect | Sep 17, 2025 | 0 |
| Kling Douglas F | Chief Operating Officer | 44,000 | Jul 17, 2025 | 0 |
| Marino Michael F III | See Remarks | 55,000 | Jun 3, 2025 | 0 |
| Audet Juliette Berangere | See Remarks | 15,104 | May 2, 2025 | 0 |
| Jones William A Jr | Chief Commercial Officer | 43,000 | Jan 7, 2025 | 0 |
| Forbion Capital Fund IV Cooperatief U.A. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion Growth Management B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion IV Management B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| ForGrowth NAP B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| BCIP Life Sciences Associates, LP | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS II Investco, LP | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Fund III, L.P. | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS Fund III Investments GP, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences III General Partner, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS Fund III Investments, LP | 10% Owner | – | Dec 17, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2024 (view filing)4:15 PM ET | Dec 10-11 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −462.3K | $25.40 | −$11.7M | −3.9%11.3M after | 5 lots10b5-1 |
| Nov 19, 2024 (view filing)4:15 PM ET | Nov 15-18 | 4 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −41.8K | $25.07 | −$1.05M | −0.4%11.8M after | 2 lots10b5-1 |
| Nov 15, 2024 (view filing)4:36 PM ET | Nov 13-14 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −10.9K | $25.01 | −$272.5K | −0.1%11.8M after | 2 lots10b5-1 |
| Oct 1, 2024 (view filing) | Oct 1 | Same day | Kooij Louise FrederikaChief Accounting Officer | SSale | −45.0K | $15.72 | −$707.4K | −100.0%0 after | |
| Sep 30, 2024 (view filing) | Sep 26 | 4 days | Audet Juliette BerangereChief Business Officer | PPurchase | +1.10K | $15.70 | +$17.3K | New position1.10K after | |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Davidson Michael H.Chief Executive Officer | PPurchase | +5.00K | $16.27 | +$81.3K | +2.4%209.8K after | |
| Jun 24, 2024 (view filing) | Jun 20 | 4 days | Davidson Michael H.Chief Executive Officer | PPurchase | +5.00K | $17.26 | +$86.3K | +2.5%204.8K after | |
| Mar 28, 2024 (view filing) | Mar 26 | 2 days | Topper James NDirector | PPurchase | +8.43K | $21.50 | +$181.2K | +0.3%3.01M after | |
| Mar 27, 2024 (view filing) | Mar 26 | 1 day | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −190.5K | $21.50 | −$4.10M | −100.0%0 after | |
| Feb 21, 2024 (view filing) | Feb 13 | 8 daysLate | Lange Louis GDirector | PPurchase | +5.00K | $19.00 | +$95.0K | +25.2%24.9K after |